Matches in Nanopublications for { ?s ?p "[Moreover, LY294002, a potent and specific cell-permeable inhibitor of phosphatidylinositol 3-kinases (PI3K), was selected to pretreat ovarian cancer cells to confirm whether PI3K/Akt signaling is involved in this event.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 9 of
9
with 100 items per page.
- assertion description "[Moreover, LY294002, a potent and specific cell-permeable inhibitor of phosphatidylinositol 3-kinases (PI3K), was selected to pretreat ovarian cancer cells to confirm whether PI3K/Akt signaling is involved in this event.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP1232022.RABIL6z00IoUNWH9Ciw-FzHM4Tf8LB6eIAizu5PNq4drg130_assertion description "[Moreover, LY294002, a potent and specific cell-permeable inhibitor of phosphatidylinositol 3-kinases (PI3K), was selected to pretreat ovarian cancer cells to confirm whether PI3K/Akt signaling is involved in this event.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1232022.RABIL6z00IoUNWH9Ciw-FzHM4Tf8LB6eIAizu5PNq4drg130_provenance.
- NP1232024.RACBsQmpXlqwp86UHE5kyoLWPSdAOaCesVY4H9KJi-nBU130_assertion description "[Moreover, LY294002, a potent and specific cell-permeable inhibitor of phosphatidylinositol 3-kinases (PI3K), was selected to pretreat ovarian cancer cells to confirm whether PI3K/Akt signaling is involved in this event.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1232024.RACBsQmpXlqwp86UHE5kyoLWPSdAOaCesVY4H9KJi-nBU130_provenance.
- NP1232023.RAiDt3dBoTV5ucHvWWPRl31_L9XyVK-8mCNvzJIPSHp90130_assertion description "[Moreover, LY294002, a potent and specific cell-permeable inhibitor of phosphatidylinositol 3-kinases (PI3K), was selected to pretreat ovarian cancer cells to confirm whether PI3K/Akt signaling is involved in this event.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1232023.RAiDt3dBoTV5ucHvWWPRl31_L9XyVK-8mCNvzJIPSHp90130_provenance.
- NP1232018.RAMm3k3vu47NRqKfx-o3OWpKBR77ug2TkV42z6ShBMDhg130_assertion description "[Moreover, LY294002, a potent and specific cell-permeable inhibitor of phosphatidylinositol 3-kinases (PI3K), was selected to pretreat ovarian cancer cells to confirm whether PI3K/Akt signaling is involved in this event.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1232018.RAMm3k3vu47NRqKfx-o3OWpKBR77ug2TkV42z6ShBMDhg130_provenance.
- NP1232019.RAFChJ1wEtNuXC8MfgDLswXG1EjAHp-Wvli062SH96JfM130_assertion description "[Moreover, LY294002, a potent and specific cell-permeable inhibitor of phosphatidylinositol 3-kinases (PI3K), was selected to pretreat ovarian cancer cells to confirm whether PI3K/Akt signaling is involved in this event.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1232019.RAFChJ1wEtNuXC8MfgDLswXG1EjAHp-Wvli062SH96JfM130_provenance.
- NP1232021.RAG0YFtZFNpuvmnuVHcbn1QkXx5Yfuqj3sf41tIvaFAgI130_assertion description "[Moreover, LY294002, a potent and specific cell-permeable inhibitor of phosphatidylinositol 3-kinases (PI3K), was selected to pretreat ovarian cancer cells to confirm whether PI3K/Akt signaling is involved in this event.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1232021.RAG0YFtZFNpuvmnuVHcbn1QkXx5Yfuqj3sf41tIvaFAgI130_provenance.
- NP1232025.RAGuKYKQYzo7nYNGYnG8NHlS8kCrSvoPBdQE14EV0NKyc130_assertion description "[Moreover, LY294002, a potent and specific cell-permeable inhibitor of phosphatidylinositol 3-kinases (PI3K), was selected to pretreat ovarian cancer cells to confirm whether PI3K/Akt signaling is involved in this event.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1232025.RAGuKYKQYzo7nYNGYnG8NHlS8kCrSvoPBdQE14EV0NKyc130_provenance.
- NP1232017.RA6ZEgCucL-he_bxHRkxQobZXrL8cxnsdcmQCYKRD2PTU130_assertion description "[Moreover, LY294002, a potent and specific cell-permeable inhibitor of phosphatidylinositol 3-kinases (PI3K), was selected to pretreat ovarian cancer cells to confirm whether PI3K/Akt signaling is involved in this event.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1232017.RA6ZEgCucL-he_bxHRkxQobZXrL8cxnsdcmQCYKRD2PTU130_provenance.